It is currently 17 Oct 2017, 12:05

Close

GMAT Club Daily Prep

Thank you for using the timer - this advanced tool can estimate your performance and suggest more practice questions. We have subscribed you to Daily Prep Questions via email.

Customized
for You

we will pick new questions that match your level based on your Timer History

Track
Your Progress

every week, we’ll send you an estimated GMAT score based on your performance

Practice
Pays

we will pick new questions that match your level based on your Timer History

Not interested in getting valuable practice questions and articles delivered to your email? No problem, unsubscribe here.

Close

Request Expert Reply

Confirm Cancel

Events & Promotions

Events & Promotions in June
Open Detailed Calendar

In clinical trials of new medicines, half of the subjects

  new topic post reply Question banks Downloads My Bookmarks Reviews Important topics  
Author Message
SVP
SVP
User avatar
Joined: 30 Oct 2003
Posts: 1788

Kudos [?]: 112 [0], given: 0

Location: NewJersey USA
In clinical trials of new medicines, half of the subjects [#permalink]

Show Tags

New post 31 Dec 2003, 14:40
00:00
A
B
C
D
E

Difficulty:

(N/A)

Question Stats:

100% (01:44) correct 0% (00:00) wrong based on 13 sessions

HideShow timer Statistics

18. In clinical trials of new medicines, half of the subjects receive the drug being tested and half receive a physiologically inert substance ?a placebo. Trials are designed with the intention that neither subjects nor experimenters will find out which subjects are actually being given the drug being tested. However, this intention is frequently frustrated because ____.

Which one of the following, if true, most appropriately completes the explanation?

(A) often the subjects who receive the drug being tested develop symptoms that the experimenters recognize as side effects of the physiologically active drug

(B) subjects who believe they are receiving the drug being tested often display improvements in their conditions regardless of whether what is administered to them is physiologically active or not

(C) in general, when the trial is intended to establish the experimental drug's safety rather than its effectiveness, all of the subjects are healthy

(D) when a trial runs a long time, few of the experimenters will work on it from inception to conclusion

(E) the people who are subjects for clinical trials must, by law, be volunteers and must be informed of the possibility that they will receive a placebo

Kudos [?]: 112 [0], given: 0

Senior Manager
Senior Manager
User avatar
Joined: 05 May 2003
Posts: 424

Kudos [?]: 12 [0], given: 0

Location: Aus
 [#permalink]

Show Tags

New post 31 Dec 2003, 16:15
I will go with A.
Though B seems to be close

Kudos [?]: 12 [0], given: 0

SVP
SVP
User avatar
Joined: 30 Oct 2003
Posts: 1788

Kudos [?]: 112 [0], given: 0

Location: NewJersey USA
 [#permalink]

Show Tags

New post 31 Dec 2003, 16:39
Correct answer is A. I chose B. If you guys have time please justify your answers. Your reasoning ( right or wrong ) will definitely help me and others.

Kudos [?]: 112 [0], given: 0

2 KUDOS received
Senior Manager
Senior Manager
User avatar
Joined: 05 May 2003
Posts: 424

Kudos [?]: 12 [2], given: 0

Location: Aus
 [#permalink]

Show Tags

New post 31 Dec 2003, 16:57
2
This post received
KUDOS
Trials are designed with the intention that neither subjects nor experimenters will find out which subjects are actually being given the drug being tested.

As per the expectation either the subjects or the experimenters should know who has been given the drug. But the experimenters come to know because of the side effects.

Kudos [?]: 12 [2], given: 0

SVP
SVP
User avatar
Joined: 30 Oct 2003
Posts: 1788

Kudos [?]: 112 [0], given: 0

Location: NewJersey USA
 [#permalink]

Show Tags

New post 31 Dec 2003, 17:08
Hats off to you. Unbelievable reasoning. Fantastic explaination indeed.

Kudos [?]: 112 [0], given: 0

1 KUDOS received
Manager
Manager
User avatar
Joined: 14 Apr 2014
Posts: 71

Kudos [?]: 161 [1], given: 196

In clinical trials of new medicines, half of the subjects receive the [#permalink]

Show Tags

New post 10 Dec 2014, 20:56
1
This post received
KUDOS
1
This post was
BOOKMARKED
In clinical trials of new medicines, half of the subjects receive the drug being tested and half receive a physiologically inert substance—a placebo. Trials are designed with the intention that neither subjects nor experimenters will find out which subjects are actually being given the drug being tested. However, this intention is frequently frustrated because______
Which one of the following, if true, most appropriately completes the explanation?
(A) often the subjects who receive the drug being tested develop symptoms that the experimenters recognize as side effects of the physiologically active drug
(B) subjects who believe they are receiving the drug being tested often display improvements in their conditions regardless of whether what is administered to them is physiologically active or not
(C) in general, when the trial is intended to establish the experimental drug’s safety rather than its effectiveness, all of the subjects are healthy
(D) when a trial runs a long time, few of the experimenters will work on it from inception to conclusion
(E) the people who are subjects for clinical trials must, by law, be volunteers and must be informed of the possibility that they will receive a placebo

Kudos [?]: 161 [1], given: 196

Senior Manager
Senior Manager
avatar
Joined: 02 Dec 2014
Posts: 374

Kudos [?]: 90 [0], given: 349

Location: Russian Federation
Concentration: General Management, Economics
GMAT 1: 640 Q44 V33
WE: Sales (Telecommunications)
Re: In clinical trials of new medicines, half of the subjects receive the [#permalink]

Show Tags

New post 11 Dec 2014, 05:41
Choice A is correct. The question states " that neither subjects nor experimenters will find out which subjects are actually being given the drug being tested". If " subjects who receive the drug being tested develop symptoms that the experimenters recognize as side effects of the physiologically active drug" then initial condition is violated
_________________

"Are you gangsters?" - "No we are Russians!"

Kudos [?]: 90 [0], given: 349

Manager
Manager
avatar
Joined: 05 Aug 2013
Posts: 90

Kudos [?]: 59 [0], given: 253

Location: India
WE: Information Technology (Computer Software)
Re: In clinical trials of new medicines, half of the subjects receive the [#permalink]

Show Tags

New post 11 Dec 2014, 13:21
ajaym28 wrote:
In clinical trials of new medicines, half of the subjects receive the drug being tested and half receive a physiologically inert substance—a placebo. Trials are designed with the intention that neither subjects nor experimenters will find out which subjects are actually being given the drug being tested. However, this intention is frequently frustrated because______
Which one of the following, if true, most appropriately completes the explanation?
(A) often the subjects who receive the drug being tested develop symptoms that the experimenters recognize as side effects of the physiologically active drug
(B) subjects who believe they are receiving the drug being tested often display improvements in their conditions regardless of whether what is administered to them is physiologically active or not
(C) in general, when the trial is intended to establish the experimental drug’s safety rather than its effectiveness, all of the subjects are healthy
(D) when a trial runs a long time, few of the experimenters will work on it from inception to conclusion
(E) the people who are subjects for clinical trials must, by law, be volunteers and must be informed of the possibility that they will receive a placebo



Can you please post OE for this question??

Kudos [?]: 59 [0], given: 253

1 KUDOS received
Manager
Manager
User avatar
Joined: 23 Oct 2014
Posts: 103

Kudos [?]: 57 [1], given: 66

Concentration: Marketing
Re: In clinical trials of new medicines, half of the subjects receive the [#permalink]

Show Tags

New post 11 Dec 2014, 20:10
1
This post received
KUDOS
In clinical trials of new medicines, half of the subjects receive the drug being tested and half receive a physiologically inert substance—a placebo. Trials are designed with the intention that neither subjects nor experimenters will find out which subjects are actually being given the drug being tested. However, this intention is frequently frustrated because______

Which one of the following, if true, most appropriately completes the explanation?

The clinical trials are designed so that no on will know which subject is given the actual drug. To complete the explanation you must find out how this design can be compromised. Essentially, find out what can alert either the subjects or the experimenters who has the real drug.

(A) often the subjects who receive the drug being tested develop symptoms that the experimenters recognize as side effects of the physiologically active drug
Bingo. If the experimenter knows what the symptoms are and the subject is exhibiting the symptoms then the experimenter will know that this subject has the real drug.

(B) subjects who believe they are receiving the drug being tested often display improvements in their conditions regardless of whether what is administered to them is physiologically active or not
This actually will enforce the design. If everyone, including the subjects with the placebo, has the same results then the design holds true. There is no way to figure out who has the real drug or who has the placebo.

(C) in general, when the trial is intended to establish the experimental drug’s safety rather than its effectiveness, all of the subjects are healthy
This is irrelevant. The trial's intent does nothing to compromise the design of the trial.

(D) when a trial runs a long time, few of the experimenters will work on it from inception to conclusion
This does not compromise the design of the trial.

(E) the people who are subjects for clinical trials must, by law, be volunteers and must be informed of the possibility that they will receive a placebo
Whether or the subject is a volunteer does not compromise the design of the trial.

Kudos [?]: 57 [1], given: 66

GMAT Club Legend
GMAT Club Legend
User avatar
Joined: 01 Oct 2013
Posts: 10130

Kudos [?]: 261 [0], given: 0

Premium Member
Re: In clinical trials of new medicines, half of the subjects [#permalink]

Show Tags

New post 13 Feb 2016, 00:26
Hello from the GMAT Club VerbalBot!

Thanks to another GMAT Club member, I have just discovered this valuable topic, yet it had no discussion for over a year. I am now bumping it up - doing my job. I think you may find it valuable (esp those replies with Kudos).

Want to see all other topics I dig out? Follow me (click follow button on profile). You will receive a summary of all topics I bump in your profile area as well as via email.

Kudos [?]: 261 [0], given: 0

Re: In clinical trials of new medicines, half of the subjects   [#permalink] 13 Feb 2016, 00:26
Display posts from previous: Sort by

In clinical trials of new medicines, half of the subjects

  new topic post reply Question banks Downloads My Bookmarks Reviews Important topics  


GMAT Club MBA Forum Home| About| Terms and Conditions| GMAT Club Rules| Contact| Sitemap

Powered by phpBB © phpBB Group | Emoji artwork provided by EmojiOne

Kindly note that the GMAT® test is a registered trademark of the Graduate Management Admission Council®, and this site has neither been reviewed nor endorsed by GMAC®.